NCT03948334 - A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

July 23, 2020

Study Completion Date

August 25, 2020

Conditions

Atopic Dermatitis

Interventions

DRUG

ZPL389 30mg

30mg of ZPL389; once daily

DRUG

ZPL389 50mg

50mg of ZPL389; once daily

DRUG

TCS and/or TCI

Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) were used concomitantly or intermittently based on disease severity.

Trial Locations (48)

201

Novartis Investigative Site, Kopavogur

3000

Novartis Investigative Site, Leuven

4818

Novartis Investigative Site, Breda

10002

Novartis Investigative Site, Taipei

20520

Novartis Investigative Site, Turku

20537

Novartis Investigative Site, Hamburg

22391

Novartis Investigative Site, Hamburg

30625

Novartis Investigative Site, Hanover

33647

Novartis Investigative Site, Bielefeld

40201

Novartis Investigative Site, Taichung

45324

Novartis Investigative Site, Fairborn

48149

Novartis Investigative Site, Münster

49074

Novartis Investigative Site, Osnabrück

69120

Novartis Investigative Site, Heidelberg

80337

Novartis Investigative Site, München

85101

Novartis Investigative Site, Bratislava

85340

Novartis Investigative Site, Litchfield Park

87700

Novartis Investigative Site, Memmingen

123182

Novartis Investigative Site, Moscow

191123

Novartis Investigative Site, Saint Petersburg

194354

Novartis Investigative Site, Saint Petersburg

196143

Novartis Investigative Site, Saint Petersburg

214019

Novartis Investigative Site, Smolensk

420012

Novartis Investigative Site, Kazan'

454092

Novartis Investigative Site, Chelyabinsk

M4V 1R2

Novartis Investigative Site, Toronto

00250

Novartis Investigative Site, Helsinki

07548

Novartis Investigative Site, Gera

467-8602

Novartis Investigative Site, Nagoya

060-0063

Novartis Investigative Site, Sapporo

220-6208

Novartis Investigative Site, Yokohama

221-0825

Novartis Investigative Site, Yokohama

593-8324

Novartis Investigative Site, Sakai

162 8655

Novartis Investigative Site, Shinjuku Ku

160-0023

Novartis Investigative Site, Shinjuku-ku

819 0167

Novartis Investigative Site, Fukuoka

819-0373

Novartis Investigative Site, Fukuoka

606 8507

Novartis Investigative Site, Kyoto

158 0097

Novartis Investigative Site, Tokyo

4624 VT

Novartis Investigative Site, Bergen op Zoom

02 495

Novartis Investigative Site, Warsaw

35 055

Novartis Investigative Site, Rzeszów

04141

Novartis Investigative Site, Warsaw

085 01

Novartis Investigative Site, Bardejov

934 01

Novartis Investigative Site, Levice

08901

Novartis Investigative Site, Svidník

SE1 9RT

Novartis Investigative Site, London

PO6 6AD

Novartis Investigative Site, Portsmouth